ISSN: 2161-0460

Zeitschrift für Alzheimer-Krankheit und Parkinsonismus

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Indiziert in
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Öffnen Sie das J-Tor
  • Genamics JournalSeek
  • Akademische Schlüssel
  • JournalTOCs
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • Elektronische Zeitschriftenbibliothek
  • RefSeek
  • Hamdard-Universität
  • EBSCO AZ
  • OCLC – WorldCat
  • SWB Online-Katalog
  • Virtuelle Bibliothek für Biologie (vifabio)
  • Publons
  • Genfer Stiftung für medizinische Ausbildung und Forschung
  • Euro-Pub
  • ICMJE
Teile diese Seite

Abstrakt

Analysis of Structure and Cost in an American Longitudinal Study of Alzheimer's Disease

Gokul Prabhakaran and Rajbir Bakshi

Objective: The purpose of this analysis is to understand the structure and change in costs for an established longitudinal study of Alzheimer’s disease with fixed enrollment.

Methods: The examination begins with a discussion of the design of the consortium based study and the types of data collected by the researchers. Financial statements (2005 to 2017) are analyzed and forward projections are confirmed using linear regression. Funding is broken down by institution, with looks at per patient and personnel costs.

Results: The rate of change for the costs is highly variable but correlated between institutions. Personnel costs are a critical driving factor. Per patient costs are noted to vary significantly between research institutions. The experiment will not be able to continue in its present form unless costs are brought to equilibrium with available funding. Sources of funding will need to consider opportunity costs, growth rates, and concurrent obligations as they evaluate projects.

Conclusion: The longitudinal study is currently the most effective study design for progressive diseases. Funding for research does not align with the demonstrated need.